Outcome of Haemopoietic Stem Cell Transplantation in 21 Patients With Alpha‐Mannosidosis
Journal of Inherited Metabolic Disease · 2025-07 · 48 (4)
DOI: 10.1002/jimd.70047 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 23.06.2025. Verfasst von Robert Šáhó und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Cz…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, alpha-Mannosidosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky RVO, Ministerstvo Školství, Mládeže a Tělovýchovy COOPERATIO, Ministerstvo Zdravotnictví Ceské Republiky.
Abstract (Originalsprache)
The outcomes of alpha‐mannosidosis after hematopoietic stem cell transplantation (HSCT) are incompletely described. This retrospective multi‐center study evaluated the outcomes of patients who underwent HSCT for their alpha‐mannosidosis after 2010. Twenty‐one children (11 females) with enzymatically and/or genetically confirmed alpha‐mannosidosis, diagnosed at a mean age of 14 months (0–60 months), were included. The median age at HSCT was 3.9 years (10 months to 13.3 years) with a median follow‐up of 2.3 years (0.3–14.1 years). Seventy‐four percent (14/19) of patients received an unrelated graft while the rest had a matched sibling donor. Primary engraftment was reached in 17 of 21 patients; four patients required a second HSCT with successful subsequent engraftment. Nine patients had severe post‐HSCT infections, five patients developed acute graft‐versus‐host disease (GvHD) (> = grade II), and one patient had chronic GvHD. No patient died during follow‐up. Seven out of ten patients received enzyme replacement therapy both pre‐ and post‐HSCT. Among children with clinical symptoms, improvement was documented in hepatomegaly (40% of patients before HSCT, down to 10% after), recurrent infections (62%/30%), and hearing disorder (85%/65%). In 13 patients with developmental data, outcomes after HSCT suggested at least mild delays persisted post‐HSCT in the majority (85%), with some trends of higher functioning with earlier treatment. Findings suggest HSCT has shown notable improvements in safety and is associated with clinical benefit in alpha‐mannosidosis. Neurodevelopmental findings require longer‐term study to account for phenotypic diversity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Czech Republic.
- Division of Clinical Behavioral Neuroscience, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, USA.
- Center for Inherited Metabolic Diseases, Departments of Paediatrics and Adolescent Medicine and Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Ankara Bilkent City Hospital, Department of Pediatric Metabolism, Ankara, Türkiye.
- Ankara Bilkent City Hospital, Health Sciences University, Department of Pediatric Hematology/Oncology and Pediatric Bone Marrow Transplantation Unit, Ankara, Türkiye.
ORCID-Profile: Martin Magner
Förderung
- Ministerstvo Zdravotnictví Ceské Republiky RVO
- Ministerstvo Školství, Mládeže a Tělovýchovy COOPERATIO
- Ministerstvo Zdravotnictví Ceské Republiky
- Ministerstvo Školství, Mládeže a Tělovýchovy
Zitieren
APA
Šáhó, R., Formánková, R., Eisengart, J. B., Lund, A. M., Videbaek, C., Gürbüz, B. B., Özbek, N. Y., Al Jasmi, F., Ješina, P., Feillet, F., Pochon, C., Guémann, A. S., AlSayed, M., Laktina, S., Uçar, S. K., Aksoylar, S., Lund, T. C., Orchard, P. J., Eminoğlu, F. T., …, & Magner, M. (2025). Outcome of Haemopoietic Stem Cell Transplantation in 21 Patients With Alpha‐Mannosidosis. Journal of Inherited Metabolic Disease, 48(4). https://doi.org/10.1002/jimd.70047
Vancouver
Šáhó R, Formánková R, Eisengart JB, Lund AM, Videbaek C, Gürbüz BB, et al. Outcome of Haemopoietic Stem Cell Transplantation in 21 Patients With Alpha‐Mannosidosis. Journal of Inherited Metabolic Disease. 2025;48(4). doi:10.1002/jimd.70047
BibTeX
@article{h2025,
author = {Šáhó, Robert and Formánková, Renata and Eisengart, Julie B and Lund, Allan Meldgaard and Videbaek, Cecilie and Gürbüz, Berrak Bilginer and Özbek, Namık Yaşar and Al Jasmi, Fatma and Ješina, Pavel and Feillet, François and Pochon, Cécile and Guémann, Anne-Sophie and AlSayed, Moeenaldeen and Laktina, Sabine and Uçar, Sema Kalkan and Aksoylar, Serap and Lund, Troy C and Orchard, Paul John and Eminoğlu, Fatma Tuba and İleri, Talia and Kasapkara, Çiğdem Seher and Yeşilipek, Akif and Tuncel, Ali Tunç and Schulz, Ansgar and Juríčková, Katarína and Hlavatá, Anna and Santoro, Lucia and Magner, Martin},
title = {Outcome of Haemopoietic Stem Cell Transplantation in 21 Patients With Alpha‐Mannosidosis},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
volume = {48},
number = {4},
doi = {10.1002/jimd.70047}
}
EUVIMED